IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium
This study has been completed.
Sponsor:
University of Colorado, Denver
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00865202
First received: March 17, 2009
Last updated: May 26, 2017
Last verified: May 2017
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Post-operative delirium is a common and deleterious complication in elderly patients. The investigators have previously found lower levels of serum tryptophan in post-operative elderly patients who developed delirium in comparison to post-operative elderly patients who did not develop delirium. The investigators hypothesize that post-operative supplementation of L-tryptophan will reduce the duration and incidence of post-operative delirium. This study is a double-blinded placebo controlled trial of L-tryptophan supplementation in post-operative ICU patients 60 years and older. The primary outcome measure is the comparison of duration of post-operative delirium in subjects who receive L-tryptophan supplementation versus a similar appearing control.
| Condition | Intervention | Phase |
|---|---|---|
| Post-operative Delirium | Drug: L-tryptophan supplementation Drug: placebo | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Care Provider, Investigator, Outcomes Assessor Primary Purpose: Prevention |
| Official Title: | A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium |
Resource links provided by NLM:
Further study details as provided by University of Colorado, Denver:
Primary Outcome Measures:
- Duration of Post-operative Delirium [ Time Frame: post-operatively daily in ICU until discharged from ICU ]
Secondary Outcome Measures:
- Incidence of Post-operative Delirium [ Time Frame: post-operatively daily in ICU until discharged from ICU ]
The incidence and/or duration of excitatory (hyperactive and mixed) post-operative delirium, diagnosed by the Confusion Assessment Method-ICU (CAM-ICU) with the Richmond Agitation Sedation Score (RASS), will be reduced with enteral L-tryptophan supplementation (1 gm TID for the first 3 post-op days), compared to placebo, in older patients (≥ 60 years) undergoing operations requiring ICU admission.
The incidence and/or duration of all types of post-operative delirium, diagnosed by the CAM-ICU with the RASS, will be reduced with enteral L-tryptophan supplementation (1 gm TID for the first 3 post-op days), compared to placebo, in older patients (≥ 60 years) undergoing operations requiring ICU admission.
- Level of Post-operative Serum Tryptophan [ Time Frame: post-operative day number two blood draw ]
- Level of Post-operative Melatonin [ Time Frame: Blood draw on post-operative day number two ]
- Length of Post-operative ICU and Hospital Stay [ Time Frame: length of post-op hospital stay ]
| Enrollment: | 301 |
| Study Start Date: | December 2008 |
| Study Completion Date: | December 2012 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: L-Tryptophan
L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
|
Drug: L-tryptophan supplementation
L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
Other Name: L-tryptophan 1 gm PO TID starting the evening of surgery
|
|
Placebo Comparator: Placebo
Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
|
Drug: L-tryptophan supplementation
L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
Other Name: L-tryptophan 1 gm PO TID starting the evening of surgery
Drug: placebo
Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
Other Name: Similar appearing placebo
|
Detailed Description:
The sudy will compare rates and duration of postoperative delirium in groups that receive L-tryptophan supplementation compared to placebo.
Eligibility| Ages Eligible for Study: | 60 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Included subjects will be 60 years and older undergoing an operation with a planned ICU admission post-operatively.
Exclusion Criteria:
-
Medications that, when combined with tryptophan, increase the risk of serotonin syndrome. The classes of medications include:
- monoamine oxidase inhibitors
- selective serotonin reuptake inhibitors
- serotonin-norepinephrine reuptake inhibitors
- triptans
- opioids
- central nervous system stimulants
- bupropion
- St. John's Wort
- Patients who undergo an operation on their brain.
- Factors which prevent delirium assessment with the CAM-ICU: vision impairment or non-fluent English speakers.
-
A lowered seizure threshold including:
- history of seizure disorder
- alcohol abuse defined by a high AUDIT score (>8 females and >13 males)
- benzodiazepine or barbiturate abuse within three months of the study
- OR a positive urine toxicology screen for alcohol, benzodiazepines or barbiturates.
- Significant liver disease (Child's class B or greater) or significant renal disease (Creatinine ≥2.0).
- History of Huntington's or Addison's disease. (As requested by the FDA)
- History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia). (As requested by the FDA)
- Women who are not post-menopausal. (As requested by the FDA)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00865202
Please refer to this study by its ClinicalTrials.gov identifier: NCT00865202
Locations
| United States, Colorado | |
| Denver Veterans Affairs Medical Center | |
| Denver, Colorado, United States, 80220 | |
Sponsors and Collaborators
University of Colorado, Denver
Investigators
| Principal Investigator: | Thomas Robinson, MD | University of Colorado, Denver |
More Information
Publications:
| Responsible Party: | University of Colorado, Denver |
| ClinicalTrials.gov Identifier: | NCT00865202 History of Changes |
| Other Study ID Numbers: |
08-0543 |
| Study First Received: | March 17, 2009 |
| Results First Received: | May 27, 2014 |
| Last Updated: | May 26, 2017 |
Keywords provided by University of Colorado, Denver:
|
delirium surgery operation geriatric complication |
Additional relevant MeSH terms:
|
Delirium Confusion Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
Neurocognitive Disorders Mental Disorders Tryptophan Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs |
ClinicalTrials.gov processed this record on July 27, 2017